Botulinum toxin in facial aesthetics and the processing of emoticons




Botulinum toxin type A; Facial expression; Emotions; Major depressive disorder.


The action of botulinum toxins is the result of their powerful ability to inhibit the release of neurotransmitters. In this sense, botulinum toxins have a wide range of indications, both cosmetic and therapeutic. The aim of this study was to carry out a bibliographical survey on the use of botulinum toxin Type A (BoNT/A) in facial aesthetics and emotion processing. To this end, we evaluated randomized clinical trials (RCTs) that analyzed the effects of BoNT/A on patients with mood disorders, with an emphasis on depression. The search was carried out in the PubMed, SCIELO, Web of Science and LILACS databases, using DeCS/MeSH descriptors, and included articles published in Portuguese and English between 2003 and 2023. After applying the criteria, 13 articles were selected for analysis. Overall, BoNT/A was shown to be an alternative that significantly improved facial signs of depression when compared to placebo in the studies carried out. In most of the RCTs, BoNT/A was applied to the mimic muscles of the upper third of the face, in the glabellar area, which was related to the improvement of mood disorders targeted by facial feedback. Thus, clinical evidence suggests that the management of emotional disorders includes the use of botulinum toxin therapy.


Adelmann, P. K. & Zajonc, R. B. (1989) Facial efference and the experience of emotion. Annual Review of Psychology, 40, 249–280. 10.1146/ 001341.

Arnone, D., Galadari, H., Rodgers, C. J., Östlundh, L., Aziz, K. A., Stip, E. & Young, A. H. (2021) Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta- regression analyses of double-blind randomised controlled trials. J. Psychopharmacol, 35, 910–918. 10.1177/0269881121991827.

Arnone D. (2019) Functional MRI findings, pharmacological treatment in major depression and clinical response. Prog Neuro Psychopharmacol Biol Psychiatry, 91, 28–37. 10.1016/j.pnpbp.2018.08.004.

Arnone, D., Job, D., Selvaraj, S., Abe, O., Amico, F., Cheng, Y. (2016) Computational meta-analysis of statistical parametric maps in major depression. Hum Brain Mapp, 37, 393–404. 10.1002/hbm.23108.

Arnone, D., McIntosh, A. M., Ebmeier, K. P., Munafò, M. R., & Anderson, I. M. (2012) Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol, 22, 1–16. 10.1016/j.euroneuro.2011.05.003.

Al Abdulmohsen, T. & Kruger, T. H. (2011) The contribution of muscular and auditory pathologies to the symptomatology of autism. Med. Hypotheses, 77, 1038–1047. 10.1016/j.mehy.2011.08.044.

Ambrosi, E., Arciniegas, D. B., Madan, A., Curtis, K. N., Patriquin, M. A., & Jorge, R. E. (2017) Insula and amygdala resting- state functional connectivity differentiate bipolar from unipolar depression. Acta Psychiatr Scand, 136, 129–39. 10.1111/acps.12724.

Aston-Jones, G., Rajkowski, J., Kubiak, P., Valentino, R. J., & Shipley, M. T. (1996) Role of the locus coeruleus in emotional activation. Prog Brain Res, 107, 379-402.

Barbas, H., & De Olmos, J. (1990) Projections from the amygdala to basoventral and mediodorsal prefrontal regions in the rhesus monkey. J Comp Neurol, 300, 549-571.

Baumeister, J. C., Papa, G., & Foroni, F. (2016) Deeper than skin deep—The effect of botulinum toxin-A on emotion processing. Toxicon, 118, 86–90. 10.1016/j.toxicon.2016.04.044.

Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., & Undurraga, J. (2017) Morbidity in depressive disorders. Psychother Psychosom, 86, 65–72.

Baldessarini, R. J., & Marsh, E. (1990) Fluoxetine and side effects. Arch Gen Psychiatry, 47, 191–192.

Banegas, R. A., Farache, F., Rancati, A., Chain, M., Gallagher, C. J., Chapman, M. A., et al. (2013) The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina. Aesthet Surg J, 33, 39–45. 10.1177/1090820x13503475.

Berkowitz, A. L. (2018) Tetanus, botulism, and diphtheria. Continuum (Minneap Minn), 24, 1459–1488. 10.1212/CON.0000000000000651.

Bernard, J. F., & Besson, J. M. (1990) The spino(trigemino)pontoamygdaloid pathway: electrophysiological evidence for an involvement in pain processes. J Neurophysiol, 63, 473-490.

Berntson, G. G., Sarter, M., & Cacioppo, J. T. (2003) Ascending visceral regulation of cortical affective information processing. Eur J Neurosci, 18, 2103-2109.

Brennan, C. (2016) Botulinum toxin type-A (BoNT-A) injections of the corrugator muscles for aesthetics and depression? Plast Surg Nurs, 36, 167–9. 10.1097/PSN.0000000000000159.

Brin, M. F., Boodhoo, T. I., Pogoda, J. M., James, L. M., Demos, G., Terashima, Y., Gu, J., Eadie, N., & Bowen, B. L. (2009) Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J. Am. Acad Dermatol, 61, 961–970. 10.1016/j.jaad.2009.06.040.

Brin, M. F., Durgam, S., Lum, A., James, L., Liu, J., Thase, M. E., et al. (2020) OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol, 35, 19–28. 10.1097/YIC.0000000000000290.

Brizola, J. & Fantin, N. (2016) Revisão da Literatura e Revisão Sistemática da Literatura. Revista de Educação do Vale do Arinos, RELVA, Juara/MT/Brasil, v. 3, n. 2, p. 23-39, jul./dez.

Brown, S. L., & Schwartz, G. E. (1980) Relationships between facial electromyography and subjective experience during affective imagery. Biol Psychol, 11, 49-62.

Bulnes L. C., Mariën P., Vandekerckhove M., Cleeremans A. (2019) The effects of Botulinum toxin on the detection of gradual changes in facial emotion. Sci. Rep, 9, 11734. 10.1038/s41598-019-48275-1.

Carruthers, J., Rivkin, A., Donofrio, L., Bertucci, V., Somogyi, C., Lei, X., Davis, P. G., Campo, A., & Beddingfield, F. C. (2015) A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery, 41(6), 702–711. 10.1097/DSS.0000000000000357.

Carruthers A., Cohen J. L., Cox S. E., De Boulle K., Fagien S., Finn C. J., Flynn T., Lowe N. J., Raspaldo H., Sommer B., et al. (2017) Facial aesthetics: Achieving the natural, relaxed look. J. Cosmet. Laser Ther, 9(1), 6–10. 10.1080/17429590701523927.

Carruthers, J. D., Glogau, R. G., & Blitzer, A. (2008) Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies —consensus recommendations. Plast Reconstr Surg, 121(5 Suppl), 5S–30S; quiz 31S-36S.

Carr, L., Iacoboni, M., Dubeau, M. C., Mazziotta, J. C., & Lenzi, G. L. (2003) Neural mechanisms of empathy in humans: a relay from neural systems for imitation to limbic areas. Proc Natl Acad Sci USA, 100, 5497-5502.

Ceolato C., Charles E., Clément J. P., & Ranoux D. (2018) Botulinum toxin in the treatment of resistant depressive disorder: Comparison of 2 facial injection sites. Toxicon, 156 (Suppl. S1), 15.10.1016/j.toxicon.2018.11.041.

Costa, A. C. F., Silva, E. C. D., & Gondim, D. V. (2022) Botulinum Toxin in Facial Aesthetics Affects the Emotion Process: A Meta-analysis of Randomized Controlled Trials. Clin Psychopharmacol Neurosci, 30, 20(4), 600-608. 10.9758/cpn.2022.20.4.600.

Darwin C. R. (1872) The expression of emotion in man and animals Murray, London.

Chughs, C. A., Jung, S., Kruger, T. H. C., & Wollmer, M. A. (2018) Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract, 24, 15–20. 10.1097/PRA.0000000000000277.

Craig, A. D. (2002) How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci, 3, 655–666. 10.1038/nrn894.

Cristel, R. T., Gandhi, N. D., Issa, T. Z., Kola, E., Demesh, D., & Dayan, S. H. (2021). A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic. Aesthetic surgery journal, 41(9), NP1199–NP1205.

Critchley, H. D., Wiens, S., Rotshtein, P., Ohman, A., & Dolan, R. J. (2004) Neural systems supporting interoceptive awareness. Nat. Neurosci, 7, 189–195. 10.1038/nn1176.

Ceylan, D., Erer, S., Zarifoglu, M., Turkes, N., & Ozkaya, G. (2019) Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci, 40, 725–31. 10.1007/s10072-019-3719-9.

Cosio T. & Campione E. (2019) A new hypothesis in botulin therapy for depression: Insula cortex modification. Dermatol. Ther, 32, 13008. 10.1111/dth.13008.

Coles, N. A., Larsen, J. T., Kuribayashi, J., & Kuelz, A. (2019) Does Blocking Facial Feedback Via Botulinum Toxin Injections Decrease Depression? A Critical Review and Meta-Analysis. Emot. Rev, 11, 294–309. 10.1177/1754073919868762.

Cohen, I. V., Makunts, T., Atayee, R., & Abagyan, R. (2017) Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Sci. Rep, 7, 1450. 10.1038/s41598-017-01590-x.

Clayton, A., Keller, A., & Mcgarvey, E. L. (2006) Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord, 91, 27–32. 2006.

Dadretto, M., Davies, M. S., Pfeifer, J. H., Scott, A. A., Sigman, M., Bookheimer, S. Y., & Iacoboni, M. (2006) Understanding emotions in others: mirror neuron dysfunction in children with autism spectrum disorders. Nat Neurosci, 9, 28-30. 2006.

Davis, J. I., Senghas, A., Brandt, F., & Ochsner, K. N. (2010) The effects of BOTOX injections on emotional experience. Emotion, 10, 433–440. 10.1037/a0018690.

Dayan, S. H., Arkins, J. P., Patel, A. B., & Gal, T. J. (2010) A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin types an injection on quality of life and self-esteem. Dermatol Surg, 36(Suppl 4), 2088–97.

Dayan, S. H., Lieberman, E. D., Thakkar, N. N., Larimer, K. A., et al. (2008) Botulinum toxin a can positively impact first impression. Dermatol Surg, 34(Suppl 1), S40–7.

Demyttenaere, K., Enzlin, P., Dewé, W., Boulanger, B., De Bie, J., De Troyer, W., & Mesters, P. (2001) Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psych, 62, 30–33.

Dolensek, N., Gehrlach, D. A., Klein, A. S., & Gogolla, N. (2020) Facial expressions of emotion states and their neuronal correlates in mice. Science, 368, 89–94. 10.1126/science.aaz9468.

Ênia, J. R. N. et al. (2021) Toxina botulínica no tratamento da paralisia facial: um tratamento reabilitador minimamente invasivo. Research, Society and Development, v. 10, n. 5, p. e40510515204-e40510515204.

Ekman, W. V. (1978) Friesen Facial action coding system: a technique for the measurement of facial movement Consulting Psychologists Press, Palo Alto.

Feng Z, Sun Q, He L, Wu Y, Xie H, Zhao G, et al. (2015) Optimal dosage of botulinum toxin type A for treatment of glabellar frown lines: efficacy and safety in a clinical trial. Dermatol Surg, 41(Suppl 1), S56–63. 10.1097/dss.0000000000000265.

Finzi E., & Rosenthal, N. E. (2014) Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res, 52, 1–6. 10.1016/j.jpsychires.2013.11.006.

Finzi E. & Rosenthal N. E. (2016) Emotional proprioception: Treatment of depression with afferent facial feedback. J Psychiatr Res, 80, 93–96. 10.1016/j.jpsychires.2016.06.009.

Finzi E. & Wasserman E. (2006) Treatment of depression with botulinum toxin A: A case series. Dermatol. Surg, 32, 645–649. 10.1097/00042728-200605000-00007.

Finzi E., Kels L., Axelowitz J., Shaver B., Eberlein C., Krueger T. H. & Wollmer M. A. (2018) Botulinum toxin therapy of bipolar depression: A case series. J. Psychiatr. Res, 104, 55–57. 10.1016/j.jpsychires.2018.06.015.

França K & Lotti T. (2017) Botulinum toxin for the treatment of depression. Dermatol Ther, 30, 12422. 10.1111/dth.12422.

Furukawa, T. A., Maruo, K., Noma, H., Tanaka, S., Imai, H., Shinohara, K., et al. (2018) Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand, 137, 450–8. 10.1111/acps.12886.

Greden, J. F., Genero, N., & Price, H. L. (1985) Agitation-increased electromyogram activity in the corrugator muscle region: a possible explanation of the “Omega sign”? Am J Psychiatry, 142, 348–51.

Gomes-Oliveira, M. H., Gorenstein, C., Lotufo Neto, F., Andrade, L. H., & Wang, Y. P. (2012). Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. Brazilian Journal of Psychiatry, 34(4), 389–394.

Gilmer, M. H. Trivedi, A. J. Rush, S. R. Wisniewski, J. Luther, R. H. Howland, et al. (2005) Factors associated with chronic depressive episodes: a preliminary report from the STAR- D project. Acta Psychiatrica Scandinavica, 112, 425-433.

Hambleton P. (1992) Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol, 239, 16--20.

Havas, D. A., Glenberg, A. M., Gutowski, K. A., Lucarelli, M. J. & Davidson, R. J. (2010) Cosmetic use of botulinum toxin-a affects processing of emotional language. Psychol. Sci, 21, 895–900. 10.1177/0956797610374742.

Hexsel D., Brum C., Siega C., Schilling-Souza J., Dal’Forno T., Heckmann M., & Rodrigues T.C. (2013) Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol. Surg, 39, 1088–1096. 10.1111/dsu.12175.

Heckmann M., Teichmann B., Schröder U., Sprengelmeyer R. & Ceballos-Baumann A. O. (2003) Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J. Am. Acad. Dermatol, 49, 213–216. 10.1067/S0190-9622(03)00909-5.

Hennenlotter, A., Dresel, C., Castrop, F., Ceballos-Baumann, A. O., Wohlschläger, A. M., & Haslinger, B. (2009) The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex, 19, 537–542. 10.1093/cercor/bhn104.

Heller, A. S., Lapate, R. C., Mayer, K. E., & Davidson, R. J. (2014) The face of negative affect: Trial‐by‐trial corrugator responses to negative pictures are positively associated with amygdala and negatively associated with ventromedial prefrontal cortex activity. Journal of Cognitive Neuroscience, 26(9), 2102–2110. 10.1162/jocn_a_00622.

James, W. (1890) The principles of psychology Holt, New York. Henry Holt, 10.1037/10538-000.

Jankovic, J. (2004) Botulinum toxin in clinic al practice. J Neurol Neurosurg Psychiat ry, 75, 951-7.

Jankovic, J. (2017) botulinum toxin: state of the art. Mov Disord, 32, 1131–8. 10.1002/mds.27072.

Jancke, L. (1996) Facial EMG in an anger-provoking situation: individual differences in directing anger outwards or inwards. Int J Psychophysiol, 23, 207-214.

Katon, W. J. (2011) Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci, 13, 7–23.

Khademi, M., Roohaninasab, M., Goodarzi, A., Seirafianpour, F., Dodangeh, M. & Khademi, A. (2021) The healing effects of facial BOTOX injection on symptoms of depression alongside its effects on beauty preservation. J. Cosmet. Dermatol, 20, 1411–1415. 10.1111/jocd.13990.

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., et al. (2003) National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289, 3095–3105.

Kim, M. J., Neta, M., Davis, F. C., Ruberry, E. J., Dinescu, D., Heatherton, T. F., Stotland, M. A. & Whalen, P. J. (2014) Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: Preliminary findings from an A-B-A design. Biol. Mood Anxiety Disord, 4, 11, 10.1186/2045-5380-4-11.

Larsen, R. J., & Kasimatis, K. (1992) Frey Facilitating the furrowed brow: an unobtrusive test of the facial feedback hypothesis applied to unpleasant affect Cognition Emotion, 6, 321-338.

Lee, H., Heller, A. S., Van Reekum, C. M., Nelson, B., & Davidson, R. J. (2012) Amygdala‐prefrontal coupling underlies individual differences in emotion regulation. Neuroimage, 62(3), 1575–1581. 10.1016/j.neuroimage.2012.05.044.

Lewis, M. B. (2018) The interactions between botulinum-toxin-based facial treatments and embodied emotions. Sci Rep, 8, 14720. 10.1038/s41598-018-33119-1.

Lewis, M. B. & Bowler, P. J. (2009) Botulinum toxin cosmetic therapy correlates with a more positive mood. J. Cosmet. Dermatol, 8, 24–26. 10.1111/j.1473-2165.2009.00419.x.

Ledoux, J. E. (2000) Emotion circuits in the brain. Annu Rev Neurosci, 23, 155-184.

Leuchter, A. F., Cook, I. A., Hunter, A. M., Cai, C., & Horvath, S. (2012) Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression. PLOS One, 7, e32508. 10.1371/journal.pone.0032508.

Li, Y., Liu, T., & Luo, W. (2021) Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective. Front Psychiatry, 23, 12:584416. 10.3389/fpsyt.2021.584416.

Li, Y., Liu, J., Liu, X., Su, C. J., Zhang, Q. L., Wang, Z. H., Cao, L. F., Guo, X. Y., Huang, Y., Luo, W., et al. (2019) Antidepressant-Like Action of Single Facial Injection of Botulinum Neurotoxin A is Associated with Augmented 5-HT Levels and BDNF/ERK/CREB Pathways in Mouse Brain. Neurosci. Bull, 35, 661–672. 10.1007/s12264-019-00367-8.

Lyu Alan, F. Y., Lulu, T., Xueyan, G., Jing, L., Yixian, H., Xuping, Z., et al. (2019) Clinical study on the efficacy and safety of botulinum toxin A in the treatment of Parkinson′s disease with depression. Chin J Neurol, 52, 745–51.

Ludwig, R. J., & Welch, M. G. (2019) Darwin's other dilemmas and the theoretical roots of emotional connection. Frontiers in Psychology, 10, 683. 10.3389/fpsyg.2019.00683.

Magid, M., Reichenberg, J. S., Poth, P. E., Robertson, H. T., LaViolette, A. K., Kruger, T. H., et al. (2014) Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 75, 837–844. 10.4088/JCP.13m08845.

Magid, M., Finzi, E., Kruger, T. H., Robertson, H. T., Keeling, B. H., Jung, S., Reichenberg, J. S., Rosenthal, N. E. & Wollmer, M. A. (2015) Treating depression with botulinum toxin: A pooled analysis of randomized controlled trials. Pharmacopsychiatry, 48, 205–210. 10.1055/s-0035-1559621.

Makunts T., Wollmer M. A. & Abagyan R. (2020) Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Sci. Rep, 10, 12851. 10.1038/s41598- 020-69773-7. 2020.

Marchand-Pauvert, V., Aymard, C., Giboin, L. S., Dominici, F., Rossi, A., & Mazzocchio, R. (2013) Beyond muscular effects: Depression of spinal recurrent inhibition after botulinum neurotoxin A. Journal of Physiology, 591(4), 1017–1029. 10.1113/jphysiol.2012.239178.

Merikangas, K. R., Ames, M., Cui, L., Stang, P. E., Ustun, B., Von Korff, M., & Kessler, R. C. (2007) The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psych, 64, 1180–1188.

Milev R. (2015) Response of depression to botulinum toxin treatment: agitation as a predictor. Front Psychiatry, 6, 55. 10.3389/fpsyt.2015.00055.

Molina, B., Grangier, Y., Mole, B., Ribe, N., Martín Diaz, L., Prager, W., Paliargues, F., & Kerrouche, N. (2015) Patient satisfaction after the treatment of glabellar lines with botulinum toxin type A (speywood unit): A multi‐centre European observational study. Journal of the European Academy of Dermatology and Venereology, 29(7), 1382–1388. 10.1111/jdv.12881.

Mclntosh, D. N. (1996) Facial feedback hypotheses: evidence, implications, and directions. Motivation and Emotion, 20, 121–47.

Nakatani, H., & Yamaguchi, Y. (2014) Quick concurrent responses to global and local cognitive information underlie intuitive understanding in board‐game experts. Scientific Reports, 4, 5894. 10.1038/srep05894.

Nestor, M. S., Fischer, D. L., & Arnold, D. (2020) "Masking" our emotions: bot-ulinum toxin, facial expression, and well- being in the age of COVID-19. J Cosmet Dermatol, 19, 2154–2160. 10.1111/jocd.13569.

Orsini, M., Leite, M. A., Chung, T. M., Bocca, W., de Souza, J. A., de Souza, O. G., et al. (2015) Botulinum neurotoxin type a in neurology: update. Neurol Int, 7, 5886. 10.4081/ni.2015.5886.

Parsaik, A. K., Mascarenhas, S. S., Hashmi, A., Prokop, L. J., John, V., Okusaga, O., & Singh, B. (2016) Role of Botulinum Toxin in Depression. J. Psychiatr. Pract, 22, 99–110. 10.1097/PRA.0000000000000136.

Park, M. Y., & Ahn, K. Y. (2021) Scientific review of the aesthetic uses of botulinum toxin type A. Arch Craniofac Surg, 22, 1–10. 10.7181/acfs.2021.00003

Pezzoli, S., Emsell, L., Yip, S. W., Dima, D., Giannakopoulos, P., Zarei, M., et al. (2018) Meta-analysis of regional white matter volume in bipolar disorder with replication in an independent sample using coordinates, T-maps, and individual MRI data. Neurosci Biobehav Rev, 84, 162–70. 10.1016/j.neubiorev.2017.11.005.

Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev, 69, 200–235. 10.1124/pr.116.012658.

Pollack, M. H., & Rosenbaum, J. F. (1987) Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psych, 48, 3–8.

Qian, H., Shao, F., Lenahan, C., Shao, A., & Li, Y. (2020) Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Psychiatry, 11, 603087. 10.3389/fpsyt.2020.603087.

Rajmohan, V., & Mohandas, E. (2007) Mirror neuron system. Indian J Psychiatry (2007) 49:66–9. 10.4103/0019- 5545.31522.

Remick, R. A., Froese, C., & Keller, F. D. (1989) Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry, 13, 497–504.

Rolls, E. T., O’Doherty, J., Kringelbach, M. L., Francis, S., Bowtell, R., & McGlone, F. (2003) Representations of pleasant and painful touch in the human orbitofrontal and cingulate cortices. Cereb Cortex. 13: 308-317.

Rosales, R. L., Bigalke, H., & Dressler, D. (2006) Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol, 13(Suppl 1), 2–10. 10.1111/j.1468-1331.2006.01438.x.

Robinson, M., Iyengar, S., Bymaster F., Clark, M., & Katon, W. (2009) Depression and pain. Front Biosci, 14, 5031–51. 10.2741/3585.

Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., Niederehe G., Thase M. E., Lavori P. W., Lebowitz B. D., et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry, 163, 1905–1917. 10.1176/ajp.2006.163.11.1905.

Shilpa, P. S., Kaul, R., Sultana, N., & Bhat, S. (2014) Botulinum toxin: The Midas touch. J Nat Sci Biol Med, 5, 8–14. 10.4103/0976-9668.127274.

Scott, A. B., Rosenbaum, A. & Collins, C. C. (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol, 12, 924–927.

Sposito, M. M. M. (2009) Artigo de revisão: Toxina Botulínica do Tipo A: mecanismo de ação. Acta Fisiatr, 16(1), 25-37.

Simpson, L. L. (2000) Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie, 82(9), 943–953.

Soussingnan R. (2002) Duchenne smile, emotional experience, and autonomic reactivity: a test of the facial feedback hypothesis. Emotion, 2, 52–74. 10.1037/1528-3542.2.1.52.

Shorter E. (2018) Darwin’s contribution to psychiatry. Br. J. Psychiatry, 195, 473–474. 10.1192/bjp.bp.109.072116.

Schwartz G. E., Fair P. L., Salt P., Mandel M. R. & Klerman G. L. (1976) Facial muscle patterning to affective imagery in depressed and nondepressed subjects. Science, 192, 489–491. 10.1126/science.1257786.

Sommer B., Zschocke I., Bergfeld D., Sattler G. & Augustin M. (2003) Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol. Surg, 29, 456–460.

Sykianakis D., Stratigos A., Chatziioannou A. & Christodoulou C. (2022) Botulinum toxin type A treatment is associated with improved social and psychological behavior: A retrospective study. J. Cosmet. Dermatol, 21, 142–148. 10.1111/jocd.14627.

Serretti A, Olgiati P & Colombo C. (2005) Components of self-esteem in affective patients and non-psychiatric controls. J Affect Disord, 88, 93–8.

Sesardic T. (2012) Bioassays for evaluation of medical products derived from bacterial toxins. Curr Opin Microbiol, 15, 310–6. 10.1016/j.mib.2012.05.008.

Serna, M. C., Cruz I, Real J, Gascó E & Galván L. (2010) Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry, 25(4), 206-13. 10.1016/j.eurpsy.2009.07.012.

Strack, F., Martin L. L., & Stepper S. (1988) Inhibiting and facilitating conditions of the human smile: a nonobtrusive test of the facial feedback hypothesis. J Pers Soc Psychol, 54, 768–77. 10.1037//0022-3514.54.5.768. 1988.

Schulze J., Neumann I., Magid M., Finzi E., Sinke C., Wollmer M.A. & Krüger T.H.C. (2021) Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis. J. Psychiatr, 135, 332–340. 10.1016/j.jpsychires.2021.01.016.

Thaipisuttikul P, Ittasakul P, Waleeprakhon P, Wisajun P & Jullagate S. (2014) Psychiatric comorbidities in patients with major depressive disorder. Neuropsychiatr Dis Treat, 10, 2097–2103.

Warden D, Rush A. J, Trivedi M. H, Fava M., & Wisniewski S. R. (2007) The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports, 9, 449–459.

Wise, T., Marwood, L., Perkins, A. M., Herane-Vives, A., Williams, S. C. R., Young, A. H., et al. (2018) A morphometric signature of depressive symptoms in unmedicated patients with mood disorders. Acta Psychiatr Scand, 138, 73–82. 10.1111/acps.12887.

Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P., & Rzany B. (2005) Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol, 152, 342–5. 10.1111/j.1365-2133.2004.06334.x.

Wollmer M. A., de Boer C., Kalak N., Beck J., Götz T., Schmidt T., et al. (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res, 46, 574–581. 10.1016/j.jpsychires.2012.01.027.

Wollmer, M. A., Kalak, N., Jung, S., de Boer, C., Magid, M., Reichenberg, J. S., et al. (2014) Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Front Psychiatry, 5, 36. 10.3389/fpsyt.2014.00036.

Wollmer, M. A., Magid, M., Kruger, T. H. C., & Finzi, E. (2022) Treatment of Depression with Botulinum Toxin. Toxins (Basel), 31, 14(6), 383. 10.3390/toxins14060383.

Wollmer, M. A., Magid, M., Kruger, T. H. C., & Finzi, E. (2019) The use of botulinum toxin for treatment of depression. In: Whitcup SM, Hallett M, editors. Botulinum Toxin Therapy. Handbook of Experimental Pharmacology, 263, 265–78. 10.1007/164_2019_272.

Wildb, E, R. B. M., Eyb M., Bartels, M & Grodd W. (2003) Why are smiles contagious? An fMRI study of the interaction between perception of facial affect and facial movements. Psychiatry Res, 123, 17-36. 10.1016/s0925-4927(03)00006-4.

Xavier E. C. A., Andrade L. G., Lobo L. C. (2021) Toxina Botulínica Aplicada Para Fins Terapêuticos. Revista Ibero-Americana de Humanidades, Ciências e Educação, 7(9), 513-532.

Yaraskavitch, M.; Leonard, T. & Herzog, W. (2008) Botox produces functional weakness in non-injected muscles adjacent to the target muscle. Journal of Biomechanics, 41, 4, 897–902.

Zamanian A, Ghanbari Jolfaei A, Mehran G & Azizian Z. (2017) Efficacy of Botox versus placebo for treatment of patients with major depression. Iran J Public Health, 46, 982–984.

Zajonc Rb. (1985) Emotion and facial efference: a theory reclaimed. Science, 228, 15–21. 10.1126/science.3883492.

Zhang Q., Wu W., Fan Y., Li Y., Liu J., Xu Y., Jiang C., Tang Z., Cao C., Liu T., et al. (2021) The safety and efficacy of botulinum toxin A on the treatment of depression. Brain Behav, 11, e2333. 10.1002/brb3.2333.

Zhu C., Wang K., Yu T. & Liu H. (2021) Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression. Am. J. Transl. Res, 13, 2717–2723.



How to Cite

VIEIRA, M. P. de A. C. .; SOUSA, L. S. . Botulinum toxin in facial aesthetics and the processing of emoticons. Research, Society and Development, [S. l.], v. 13, n. 1, p. e5013144736, 2024. DOI: 10.33448/rsd-v13i1.44736. Disponível em: Acesso em: 20 may. 2024.



Health Sciences